Novartis upping presence in gene therapies through $8.7bn AveXis buy
Novartis will add an AAV9 gene delivery platform and manufacturing facility through the $8.7bn (€7bn) acquisition of AveXis.
Archives for April 10, 2018
MilliporeSigma: Filling gaps in continuous bioprocessing will lower COGS
Vendors can help address technology gaps but industry must look to collaborations and internal development to create fully continuous bioprocesses, says MilliporeSigma.
Cell therapy demand means CMOs need to up their capabilities, PharmSource
There is a lack of third-party capabilities in the autologous cell therapy space says the new editor of PharmSource ahead of this year’s Interphex Convention.